small molecule

UNIRETIC

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity

CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand name	UNIRETIC
Active ingredient	HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE
Strength	12.5MG;15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2002
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.